| Oncolytic Adenovirus Coding for TNFa and IL2 (TILT-123) With Pembrolizumab or Pembrolizumab (Phase 1a) and Pegylated Liposomal Doxorubicin (Phase 1b) as Treatment for Ovarian Cancer. (NCT05271318) | TILT Biotherapeutics Ltd. | 2022-05-17 |
| A Study to Investigate LYL797 in Adults With Solid Tumors (NCT05274451) | Lyell Immunopharma, Inc. | 2022-03-29 |
| A Study of Azenosertib (ZN-c3) and Niraparib in Subjects With Platinum-Resistant Ovarian Cancer (NCT05198804) | K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc | 2022-01-27 |
| A Study to Investigate Safety and Tolerability of TransCon IL-2 β/γ Alone or in Combination With Pembrolizumab and/or TransCon TLR7/8 Agonist or Other Anticancer Therapies in Adult Participants With Locally Advanced or Metastatic Solid Tumor Malignancies (NCT05081609) | Ascendis Pharma Oncology Division A/S | 2022-01-11 |
| Phase 3 Study of Nemvaleukin Alfa in Combination With Pembrolizumab in Patients With Platinum-Resistant Epithelial Ovarian Cancer (ARTISTRY-7) (NCT05092360) | Mural Oncology, Inc | 2022-01-10 |
| A Study of DeTIL-0255 in Adults With Advanced Malignancies (NCT05107739) | Nurix Therapeutics, Inc. | 2021-12-22 |
| A Comparison of 2 Standard Doses of Bevacizumab in Combination With Chemotherapy in Epithelial Ovarian Cancer (NCT04787289) | British Columbia Cancer Agency | 2021-09-10 |
| NTX-301 Monotherapy in Advanced Solid Tumours and in Combination With Platinum-based Chemotherapy in Advanced Ovarian & Bladder Cancer and in Combination With Temozolomide in High-grade Glioma (NCT04851834) | Xennials Therapeutics Australia Pty Ltd | 2021-08-25 |
| Batiraxcept (AVB-S6-500)/Placebo in Combination With Paclitaxel in Patients With Platinum-Resistant Recurrent Ovarian Cancer (NCT04729608) | Aravive, Inc. | 2021-04-22 |
| A Study of Mitoxantrone Hydrochloride Liposome Injection in the Treatment of Relapsed Ovarian Cancer (NCT04718376) | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | 2021-01-12 |
| Chk2 Inhibitor for Recurrent EpitheliAl periToneal, fallopIan or oVarian cancEr (CREATIVE Phase IA Trial) (NCT04678102) | Seoul National University Hospital | 2020-12-17 |
| A Study of Zilovertamab Vedotin (MK-2140/VLS-101) in Participants With Solid Tumors (MK-2140-002) (NCT04504916) | VelosBio Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | 2020-10-07 |
| IN10018 in Combination With Standard Chemotherapy in High-grade Serous Epithelial Ovarian Cancer (NCT05551507) | InxMed (Shanghai) Co., Ltd. | 2020-07-27 |
| Study With Afuresertib and Paclitaxel in Platinum Resistant Ovarian (NCT04374630) | Laekna Limited | 2020-06-09 |
| Anlotinib and Niraparib Dual Therapy Evaluation in Platinum-resistant Recurrent Ovarian Cancer (NCT04376073) | Jihong Liu | 2020-05-22 |
| Efficacy of Plasmid Elenagen in Combination With Gemcitabine in Patients With Platinum-resistant Ovarian Cancer (NCT05979298) | CureLab Oncology | 2019-11-15 |
| First-in-Human Dose Expansion Study of XMT-1536 in Cancers Likely to Express NaPi2b (NCT06517485) | Mersana Therapeutics | 2019-07-30 |
| Cancer Stem Cell Assay Directed Chemotherapy in Recurrent Platinum Resistant Ovarian Cancer (NCT03949283) | Cordgenics, LLC | 2019-07-26 |
| Study of 6b11-OCIK Injection Treatment in Patients With Recurrent Drug-resistant Ovarian Cancer (NCT03542669) | Peking University People's Hospital | 2018-08-03 |
| First-in-Human Dose Escalation Study of XMT-1536 in Cancers Likely to Express NaPi2b (NCT06517433) | Mersana Therapeutics | 2017-12-12 |
| First-in-Human Study of XMT-1536 in Cancers Likely to Express NaPi2b (NCT03319628) | Mersana Therapeutics | 2017-12-12 |
| FOCUS: PCC + Bevacizumab + CA4P Versus PCC + Bevacizumab + Placebo for Subjects With Platinum Resistant Ovarian Cancer (NCT02641639) | Mateon Therapeutics | 2016-06-01 |
| H.O.P.E: Helping Ovarian Cancer Patients Cope (NCT02090582) | Duke University | 2014-04-01 |
| A Phase I/II Trial of VB-111 and Paclitaxel for Recurrent Platinum-Resistant Müllerian Cancer (NCT01711970) | Vascular Biogenics Ltd. operating as VBL Therapeutics | 2012-11-01 |